Zenas BioPharma (ZBIO), a clinical-stage biopharmaceutical company focused on developing transformative therapies for autoimmune diseases, has regulatory milestones lined up for this year.
The company's approach blends disciplined product acquisition with late-stage development, anchored by two potential franchise molecules: Obexelimab and Orelabrutinib.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.